Parkinson's disease is the second most common neurodegenerative disease that occurs due to cellular autophagy deficiency and the accumulation of alpha-synuclein in the dopaminergic neurons of the substantia nigra pars compacta (SNc) of the brainstem. The SMER28 (also known as 6-Bromo-N-prop-2-enylquinazolin-4-amine) is an autophagy inducer. In this study, the neuroprotective effects of SMER28 were evaluated on autophagy induction, antioxidant system activation, and microgliosis attenuation. The Parkinson's disease model was developed in the male Wistar rats by injection of 6-OHDA into the left striatum. Apomorphine-induced behavior assessment test and SNc cell counting were performed to investigate the neuroprotective effects of SMER28. This study examined the pharmacological roles of SMER28, especially by focusing on the autophagy (p62/ SQSTM1 and LC3II/LC3I ratio where LC3 is microtubule-associated protein 1A/1B-light chain 3), inhibiting free radicals, and activating the antioxidant system. The levels of malondialdehyde (MDA), reactive oxygen species (ROS), glutathione (GSH), GSH/glutathione peroxidase (GP X ), superoxide dismutase (SOD) activity and nuclear factor-erythroid 2-related factor-2 (Nrf2) were measured to evaluate the antioxidant activity of SMER28. Moreover, Iba-1 (ionized calcium binding adaptor molecule, indicating microgliosis) and tyrosine hydroxylase immunoreactivities were evaluated in the SNc. In the behavioral assessment, SMER28 (50 µg/kg) attenuated damages to the SNc dopaminergic neurons, characterized by improved motor function. The tissue observations revealed that SMER28 prevented the destruction of SNc neurons and attenuated microgliosis as well. It also reduced MDA and ROS production and increased GSH, GP X , SOD, and Nrf2 activities by inducing autophagy (decreasing p62 and increasing LC3II/LC3I ratio). Consequently, possibly with further studies, it can be considered as a drug for neurodegenerative diseases with proteinopathy etiology.
Introduction
Parkinson's disease is a neurodegenerative and movement disorder that affects 50% of people over the age of 85 years [1] . Even though the etiology of Parkinson's disease is not completely known, a large body of evidence has shown that factors including oxidative stress, inflammation, mitochondrial damage and protein aggregations, such as alpha-synuclein, due to autophagy and antioxidant system dysfunction are involved in the destruction of substantia nigra pars compacta (SNc) dopaminergic neurons.
The term 'autophagy', derived from the Greek meaning 'eating of self'. It is a self-degradative action that is essential for balancing energy sources at critical times in response to nutrient stress. It also plays a housekeeping role in clearing misfolded or aggregated proteins, degradation and removing damaged organelles, such as mitochondria, peroxisomes and, endoplasmic reticulum as well as eliminating intracellular pathogens. Thus, autophagy generally acts as an intracellular survival mechanism [2, 3] . The levels of autophagy in the cell decrease with aging, enhancing intracellular protein aggregate accumulation [2] . The autophagy deficiency can also be seen with age in diseases such as Parkinson's, Huntington's and Alzheimer's diseases [2] . Hence, increasing autophagy level may be used as a new therapeutic strategy in this regard [4] . Autophagy-inducing molecules such as small-molecule enhancers of rapamycin (SMER) play an important role in the autophagy induction [4] . SMER28 (also known as 6-Bromo-N-prop-2-enylquinazolin-4-amine) is an autophagy inducer. SMERs decrease the accumulation of mutant huntingtin and amyloid-β in Huntington's and Alzheimer's diseases respectively through activation of mTOR-independent autophagy [5] [6] [7] . However, the effects of SMERs in Parkinson's disease are unknown. We hypothesized that SMER28 would increase the antioxidant capacity and autophagy induction, prolonging the survival of SNc dopaminergic cells via activating the Nrf2/P62 pathway. This study investigates the pharmacological role of SMER28 with the focus on the Nrf2/P62 and oxidative stress markers in the 6-OHDA-treated rats Parkinson disease model.
Materials and Methods

Ethical Approval
The protocols for this project have been approved by the ethics committee of Qazvin University of Medical Sciences and it conforms to the provisions of the Declaration of Helsinki.
Experimental Groups and Parkinson's Disease Model Development
The male Wistar rats (purchased from the Pasteur Institute in Tehran, Iran) weighing 200-250 g were used in this study. During the examinations, they were maintained under a 12 h/12 h of light/dark cycle and given food and water ad libitum. The animals were randomly divided into four experimental groups (10 rats in each group) as follow: control (intact rats and did not receive any injections) ,sham (injection of the 0.2% ascorbate-saline solution into the left striatum), lesion (injection of 12.5 µg 6-OHDA dissolved in the 0.2% ascorbate-saline solution into the left striatum) and treatment (pretreated with intraperitoneal injection of 50 µg/kg body weight of SMER28 followed by 12.5 µg 6-OHDA-ascorbate-saline injection) groups. The Parkinson's model was developed in male Wistar rats by injection of 6-OHDA into the striatum as previously reported [8] . Each animal was anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (20 mg/kg). Rats were placed in the stereotaxic instrument (Stoelting, USA) at coordinates 3 mm lateral, 0.2 mm anterior to bregma and ventrally 5 mm below the dura matter with a flat skull position according to the rat brain atlas by Paxinos and Watson [9] . 12.5 µg of 6-OHDAHCl (Sigma-Aldrich, USA) was dissolved in 5 µl of 0.2% ice-cold ascorbate-saline solution and used within 5 min in order to create the PD rat model. For minimizing mortality, post-surgery care was done during the first week after the surgery. Intraperitoneal injection of 50 µg/kg body weight of SMER28 in the treatment group was daily administered, started 1 day before surgery to 4 weeks.
Apomorphine-Induced Behavioral Assessment
The apomorphine-induced behavioral assessment test and SNc neuronal counting were performed to investigate the neuroprotective effects of SMER28. Apomorphine-induced rotation test was performed 1 week before (baseline) and 4 weeks after the surgery. The rats were injected intraperitoneally with 0.5 mg/kg of apomorphine hydrochloride (Sigma, Germany) dissolved in 0.9% saline solution. After injection of apomorphine, the total number of contralateral 360° rotations in the rats was counted in a cylindrical clear chamber (a diameter of 35 cm and a height of 37 cm) for 60 min in the experimental groups [10] .
Rat Brains Histological Examinations
Following the behavioral testing, for Nissl staining, the rats were deeply anesthetized with halothane and transcardially perfused with 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate-buffer saline (PBS, Gibco, pH 7.4) for 30 min. Their brains were carefully removed from the skull and then carefully post-fixed for 10 h in the same solution. SN was dissected out and collected in PBS. Coronal tissue sections with the diameter of 10 µm were made from the SN at intervals of 2.4-2.9 mm from the interaural point in accordance with the Paxinos atlas [9] . Coronal paraffinembedded sections from rostral to caudal of the SNc in each animal were then transferred onto gelatinized slides and stained with 0.1% cresyl violet (Sigma, Germany) [11] . The neurons in the dense part of the SN were counted in sections aligned with 4 levels of Paxinos atlas (i.e., 2.96, 3.2, 3.8, and 4.2) as compared with the center of interaural line with the magnification of × 200. At each level, at least two sections were evaluated and the neurons with the cytoplasmic domain were counted.
Malondialdehyde Assay
Four weeks post-surgery and after the behavioral test, the left mid-brain was punched out and isolated from the rats of each group. The nigral tissue homogenized with 0.9% of sodium chloride solution. After centrifugation, the supernatant was collected to evaluate the levels of MDA. To evaluate lipid peroxidation, MDA level evaluated as previously reported [12] . The homogenate incubated in two microtubes at 37 °C for 0 and 1 h. For determination of the MDA concentration, trichloroacetic acid, and thiobarbituric acid reactive substances (TBARS) reagents were added to the homogenate supernatant [0.4 ml of TCA (5%) and 0.4 ml of TBA (0.67%)], then they mixed and incubated in boiling water for 90 min. After cooling on ice, the samples were centrifuged at 3000×g for 10 min and the absorbance was read at 532 nm by a spectrophotometer. The results were reported according to the tetraethoxypropane standard curve as nmols of MDA formation/min/mg of the protein [13] .
Reactive Oxygen Species (ROS) Assay
The mid-brain tissue homogenized with 0.9% of sodium chloride solution. After centrifugation, the supernatant collected to evaluate the levels of ROS. The bioassay tests were performed by kits according to the manufacturer's instructions (Jiancheng Bioengineering Institute, Nanjing, Jiangsu, China). The ROS level was estimated with a nonfluorescent lipophilic dye, i.e. dichlorofluorescein diacetate, which is cleaved by intracellular esterase enzymes into dichlorofluorescein and then in the presence of ROS into 2,7-dichlorofluorescein (DCF) producing fluorescence [14] . The fluorescence level is known to be directly proportional to the produced levels of the ROS and it was measured at 504 nm of excitation and 529 nm of emission. A standard curve was constructed using increasing concentrations of dichlorofluorescein incubated in parallel and the results were expressed as ng of DCF (as ROS equivalent) formed.
Evaluation of Nrf2
For evaluating Nrf2 levels, the sandwich enzyme-linked immunosorbent assay (ELISA) was performed. The level of SNc lysates was measured according to the construction of the kit (Cloud-Clone Corp., USA). The optical density was read at 450 nm and the curve was plotted based on the corresponding standards.
Glutathione (GSH)
GSH content was determined by the method of Jollow et al. [15] , with slight modification. In brief, PMS was mixed with an equal volume of sulfosalicylic acid (4%) in a 1:1 ratio (vol./vol.). The samples were incubated at 4 °C for 1 h and then centrifuged at 1200×g for 15 min at 4 °C. The assay mixture contained 0.1 ml of supernatant, 1.0 mM DTNB and 0.1 M PB (pH 7.4) in a total volume of 2.0 ml. The developed yellow color was read immediately at 412 nm. The GSH content was calculated as nanomoles of GSH per milligram of protein using a molar extinction coefficient of 13.6 × 103 M −1 cm −1 .
Glutathione Peroxidase (GPx)
GPx activity was estimated according to the procedure described by Mohandas et al. [16] . The reaction mixture consisted of phosphate buffer (0.05 M, pH 7.0), EDTA (1 mM), sodium azide (1 mM), glutathione reductase (1 EU/ ml), glutathione (1 mM), NADPH (0.2 mM), hydrogen peroxide (0.25 mM), and 0.1 ml of PMS in a final volume of 2 ml. The disappearance of NADPH at 340 nm was recorded at room temperature. The enzyme activity was quantitated by measuring the disappearance of NADPH at 340 nm GPx activity was defined as nanomoles of NADPH oxidized per minute per milligram of protein using a molar extinction coefficient of 6.22 × 10
Evaluation of Superoxide Dismutase Activity (SOD)
The SOD level was evaluated according to the previous study [14] . In summary, 3 ml of a solution containing 0.3 ml of nitro blue tetrazolium (NBT, 300 µM), 1.2 ml of sodium pyrophosphate pH 8.3, 0.2 ml of NADH (780 µM), and 0.3 ml of phenazine methosulphate (PMS, 186 µM) with 1 ml (10% w / v) of the SNc homogenate were mixed together. The reaction started by adding NADH for 90 s at 37 °C. Then, by adding 1 ml of glacial acetic acid, the reaction was terminated. Next, the mixture mixed with 4 ml of n-butanol for 15 min and centrifuged for 15 min at 15,000 rpm. After that, the butanol layer was separated and read to determine the intensity of the formazan dye at a wavelength of 560 nm. The results were presented as nmol of formazan formation/min/mg of protein.
Western Blot Analysis
The anti-LC3 (ab192890), anti-GAPDH (ab181602) and anti-SQSTM1 / p62 (ab56416) primary antibodies (all provided from Abcam Company) were used for detecting the protein in the blots as previously reported with minor modifications [17] . In brief, Protein extractions from the experimental groups performed on ice with the lysis buffer and protease inhibitor cocktail (Fermentas) added immediately to the samples and protein concentrations assessed using Bradford assay. Equivalent amounts of each cell lysate were diluted in the sample buffer, boiled at 95 °C for 10 min and then subjected to SDS-PAGE using two separate gels with the gradient running from 4 to 12% gel. The gels were transferred onto the nitrocellulose membrane (Millipore) by semi-dry transferring method (BioRad) and then, the membrane (Millipore) was blocked for 1 h at 37 °C in the TrisBuffered Saline-Tween 20 (TBST) containing 5% blocking solution (Amersham). The membrane incubated for 1 h at room temperature in the TBST containing 5% blocking solution and the recommended dilution of the primary monoclonal antibody and then washed three times 15 min each using TBST. It was then incubated for 1 h in the TBST containing 5% blocking solution containing 1:10,000 dilution of horseradish peroxidase-conjugated secondary antibody. After washing for three times 15 min each with the TBST buffer, the membrane was immersed in a mixture of equal volumes of enhanced chemiluminescence (ECL) detection solutions A and B (Amersham) and exposed to X-ray film in the dark room. The exposed films were developed using the specific solutions and then digitally photographed.
TH and Iba-1 Immunostaining
Counting of tyrosine hydroxylase (TH)-positive neurons and ionized calcium binding adaptor molecule 1 (Iba-1) immunoreactive cells within SNc were performed as previously described with minor modifications [18, 19] . Using the rat brain atlas of Paxinos and Watson [20] , the borders of the SNc (interaural 2.9-4.2 mm) were carefully dissected out in rostrocaudal sections. In order to perform immunohistochemical analysis of neuronal loss and microgliosis, sections from SNc were washed three times with PBS, blocked with 10% fetal bovine serum and 0.1% Triton-X100 for 1 h at room temperature. Endogenous peroxidase activity was blocked with 3.0% H 2 O 2 for 10 min and then they incubated with anti-tyrosine hydroxylase (Millipore, 1:400) and antiIba-1 (Wako Chemicals, dilution at 1:500) primary antibodies overnight at 4 °C. This was followed by incubation with goat anti-mouse fluorescence secondary antibodies (1:200, Cell Signaling Technologies) for 1 h at room temperature. The sections were washed three times with PBS for 5 min each and nuclei were counterstained using 4′,6-diamidino-2-phenylindole (DAPI, Roche). After final washing, sections were placed on the objective slides and mounted with Fluoromount medium (Southern Biotech). Fluorescence images were captured using the Olympus imaging system. Counting was performed blind to the treatments. All countings were done twice for each section and the average was obtained. The number of sections used for each animal was at least 12.
Statistical Analysis
All values are given in Mean ± SE. The data from cell viability and cell count were analyzed using student t-test, one-way ANOVA and Tukey's tests at the statistical significance level of 0.05.
Results
Apomorphine-Induced Behavioral Test
There was no difference between the control and sham groups at all stages of the experiment, so the results of the control group were not added. The behavioral test performed in the 1st and 4th weeks after surgery. The results showed that the mean rotation count was < 5 rounds per hour before the surgery in the all experimental groups. The average rotation count 4 weeks after the surgery was 3.5 ± 1, 48 ± 3 and 182 ± 5 rounds in the sham, treatment and lesion groups, respectively. In other words, after the surgery and inducing the Parkinson's model in the lesion group, it was observed that the mean rotations count of the animals reached 182 ± 5, indicating the SNc destruction in the animal model. SMER28 usage decreased the damages to SNc dopaminergic neurons in the treatment group, characterized by improved motor function and reduced rotations in the treatment group as compared to the lesion group. The difference in the mean rotation count between treatment and lesion groups was statistically significant (P ≤ 0.05, Fig. 1 ).
Nissl Staining
Following the behavioral assessment test, the midbrains of the animals were removed and then the tissue blocks were prepared to count the neurons using Nissl staining method. The results showed that the average neuron count in the right side (healthy area) of the SNc was 120 ± 4 in sham, 118 ± 3 in treatment and 115 ± 3 in lesion group (Fig. 2) . There was no significant difference between the groups. The average neuron count in the left side (degraded region) of the SNc Fig. 1 The effect of SMER28 on the apomorphine-induced rotational behavior 4 weeks after intrastriatal microinjection of 6-hydroxydopamine (6-OHDA). SMER 28 has successfully reduced the number of rotations in the treatment group in comparison with other groups. The values were expressed as mean ± SEM, *P < 0.05 was 119 ± 5, 75 ± 4 and 33 ± 3 in the sham, treatment, and lesion groups respectively. The differences were significant between the sham, lesion and treatment groups (P ≤ 0.05, Fig. 2 ). In the treatment group, the SMER28 inhibited neuronal degradation of the SNc and the neurons showed less decrease comparing the lesion group. The neuron count was significantly lower in the lesion group than the sham group, indicating 6-OHDA-induced degradation of SNc neurons.
Evaluation of Lipid Peroxidation and ROS Levels
Oxidative stress markers in the SNc neurons showed that higher levels of MDA and ROS (P < 0.05) were observed in the lesion group in comparison with other groups (Fig. 3a, b) . In the treatment group with SMER28, the levels of these parameters were lower than the lesion group (P < 0.05).
Evaluation of Nrf2 Activity Level
Studying the levels of nigral Nrf2 showed that its levels decreased in the lesion group with 6-OHDA usage as compared to other groups (P < 0.05). However, this reduction was prevented by SMER28 pre-treatments in the treatment group (Fig. 4a) . 
Effect of SMER28 on GSH Content
A significant decrease (P < 0.05) in GSH level was observed in Lesion group when compared to Sham group, which was restored significantly (P < 0.01) in the SMER28 treatment group as compared to Lesion group (Fig. 4b) .
Effect of SMER28 on Antioxidant Enzymes Activity in Parkinsonian Rats
The activity of antioxidant enzymes (GPx and SOD) was decreased significantly in Lesion group as compared to the Sham group. On the other hand, SMER28 administration in treatment group reduced the activity of these enzymes significantly as compared to Lesion group (Fig. 4c, d ), suggesting the neuroprotective role of SMER28 in preventing degradation of dopaminergic neurons in the SNc region.
Evaluation of Autophagy
The levels of autophagy proteins (p62, LC3II, LC3I) in the SNc neurons were investigated by Western blotting (Fig. 5a ).
The results of the Western blot band sharpness were quantitated after three trials for each protein using IMAGE J software version 1.46r (Fig. 5b) . Data showed that p62 expression level in the lesion group was significantly lower than the sham group (Fig. 5) . The LC3II/LC3I protein level ratio in the treatment group was significantly higher than the lesion group (Fig. 5b) . Decreased p62 and increased LC3II/LC3I ratio indicate increased autophagy induction in the group pretreated with SMER28.
TH and Iba-1 Immunostaining
Results of TH immunocytochemical assessment (Fig. 6a) showed that there was no significant difference between the left and right side of the sham group. In contrast, a significant decrease of tyrosine TH-positive neurons was observed in the lesion group (P < 0.005). The number of TH-positive neurons in the left side of SNc was significantly higher in the treatment group in comparison with the lesion group (P < 0.05). An increase in the number of Iba-1 positive cells was found in the lesion group in comparison with the sham group (Fig. 6b) . Administration of SMER28 at 50 µg/kg tended to decrease the number of Iba-1 positive cells. The administration of 6-OHDA significantly increased the number of Iba-1 positive cells in the SNc as compared to the sham group (Fig. 6) .
Discussion
According to our results, SMER28 resulted in an improvement of the motor behavior and reduction of apomorphineinduced rotations. It decreased the 6-OHDA-induced degradation of SNc TH-neurons and induced autophagy and activating the antioxidant defense system. After the unilateral injection of 6-OHDA into the left striatum of the animals, it is oxidized in the extracellular space and causes the oxidative stress. This stress eventually leads to the destruction of the mitochondrial complex and disruption of the mitochondrial electron transport chain. This neurotoxin is retrogradely transferred and leads to the degradation of dopaminergic neurons in the SNc and reducing of dopamine levels in the 6-OHDA-injected site and the consequent up-regulation of post-synaptic dopaminergic receptors. Apomorphine-induced behavior assessment test can evaluate the asymmetry in dopamine content on the right and left sides of the SNc. The apomorphine is a dopamine agonist and in causes the contralateral rotation of the rat to the opposite side of the affected area. In this study, we observed that SMER28 can improve animal motor functions via reducing motor asymmetry and rotational behavior.
The observed decrease in the behavioral abnormality and attenuated SNc neuronal degeneration after treatment with SMER28, leads us to assume that this protective effect may be mediated due to its antioxidant and anti-inflammation action and its ability to activate autophagy. In addition to Nissl staining, the TH immunostaining was done on experimental groups. The rate-limiting enzyme TH is responsible for dopamine synthesis in the SN. Loss of TH-positive neurons in SNc following 6-OHDA diminishes dopamine synthesis in the nigrostriatal system [21] . In our research, the number of TH-positive neurons in SNc was higher after SMER28 pretreatment. This indicates the protective property of SMER28.
We also investigated the effects of SMER28 on 6-OHDAinduced oxidative stress in the SN. MDA is a product of lipid peroxidation and is a good marker of oxidative stress in the tissue. ROS generation is a side effect of oxidative metabolism. It is precisely regulated in cells by various oxidant and antioxidant enzymes. Our results indicated that 6-OHDA induces robust of MDA and ROS generation (Fig. 3) . 6-OHDA also results in a consistent, significant decrease in the total glutathione content (Fig. 4b) , GPx (Fig. 4c ) and SOD ratio (Fig. 4d) . Administration of SMER28 can potently inhibit all of these pro-oxidative stress effects. These results imply that SMER28 may be able to prevent oxidative damage in the SN after 6-OHDA exposure. As GSH is the main antioxidant in brain cells the dysregulation of its cycle is related to the onset and progression of neurodegenerative diseases [22] . In the present study, SMER28 increased the levels of GSH (Fig. 4) .
Nrf2 activates expression of GPx and SOD enzymes which detoxifies ROS productions. We observed that SMER28 increased the expression of Nrf2 that shows its regulatory effect at the translational level as well. Nrf2 activation neutralizes the neurotoxic agents in cells such as the one that is related to 6-OHDA [23] . We showed that the nigral Nrf2 level decreased in the lesion group and its levels increased with SMER28 pretreatments. Considering the negative effects of 6-OHDA on Nrf2 expression, it is possible that SMER28 prevents the 6-OHDA-induced oxidative stress by activating Nrf2.
The protective effect of the Nrf2 pathway in PD is demonstrated in a number of studies [23] . It is shown that there is a neuroprotective effect for Nrf2 against 6-OHDA-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. This is implicated via upregulation of HO-1, GSH cysteine ligase regulatory subunit, and GSH cysteine ligase modulatory subunit in these cells [23] . Nrf2 is also involved in the upregulation of HO-1 protein in glial cells and provides a beneficial effect against the dopaminergic loss caused by The results were all normalized to the GAPDH protein levels. Each set of the results was quantified upon three independent experiments. All data have been presented as mean ± SEM 6-OHDA [24] . Cui et al. investigated the protective effect of Nrf2 against rotenone-induced dopaminergic neuronal oxidative damage in a rat model of PD. Nrf2 increased GSH levels and decreased ROS and MDA [24] . Nrf2 enhances the GSH levels and SOD activity along with a reduction in mitochondrial swelling, lipid peroxidation, protein carbonyls, and ROS. It results in a significant improvement in neuromotor coordination.
To explore the molecular mechanisms underlying the protective effects of SMER28 in the 6-OHDA rat model of PD, we evaluated the expression of P62 (autophagy reporter protein) in SN. Western blot analysis demonstrated that exposure to SMER28 resulted in a strong expression of P62 in the SN of the treatment group comparing the lesion group (Fig. 5) .
The regulation of Nrf2 activity is dependent on the ability of this protein to disengage from Keap1 and translocate to the nucleus. There is an evidence of cross-talk between this antioxidant response pathway and others pathways (e.g., adipogenic, ubiquitin, inflammatory). The development of small molecules, that mimic Nrf2 activity and/or weaken its interaction with Keap1 also represent a fertile area of pharmacologic exploration [25] .
Accumulating evidence in the literature is pointing to a key role of the autophagy-related protein p62 in the transregulation of the Nrf2-Keap1 pathway. p62 is an autophagy marker protein involved in the ubiquitin-proteasome pathway. Once phosphorylated, p62 physically interacts with the Nrf2 inhibitory protein Keap 1 and regulates Nrf2 protein stability and its transcriptional activity throughout stress response and cytoprotection gene systems [26] . Furthermore, p62 controls Keap1 autophagy-induced degradation [27] and Nrf2 itself regulates p62 gene expression, thus creating a positive feedback loop on the Nrf2 pathway [28] . The studies of Komatsu and colleagues carried out in autophagydeficient mice were the first to demonstrate a role of the p62-Nrf2 axis in the pathogenesis of hepatocellular carcinoma [28, 29] . Nrf2 is a master transcription factor responsible for gene expression of a series of anti-oxidant proteins and detoxifying enzymes in two ways known as canonical and non-canonical pathways. In the canonical pathway, Keap1, an adaptor protein of Cullin-3 ubiquitin ligase, senses electrophilic or oxidative stresses and then arrests ubiquitination of Nrf2 and inhibiting its degradation by the proteasome, leading to Nrf2 translocation and targeted gene expressions containing ARE in their sequence. Importantly, in addition to this canonical pathway, in a non-canonical mechanism of action, p62 competes with Nrf2 to bind to Keap1 and p62 attachment to Keap1 releases Nrf2 from the Keap1. So, Nrf2 translocates to the dopaminergic cell nucleus. Interestingly, this non-canonical pathway is hyperactivated in SN that highlights the p62-dependent nature of the non-canonical antioxidant defense pathway [30, 31] . The p62/SQSTM1-Keap1-Nrf2 axis may be linked to SMER28 actions in increasing the cell survival as SMER28 treatments increase p62 levels in the SN (Fig. 5) .
The autophagy deficiency may be attributed to neurodegenerative disorders such as Alzheimer's disease [32] , Parkinson's diseases [33] , amyotrophic lateral sclerosis [34] and multiple sclerosis [35] beside its immunological aspects [36] . Our results show that SMER28 activates autophagy. It increased the LC3II/LC3I ratio, indicating the activation of autophagy. Earlier researches have shown that SMER28 actually is an autophagy inducer [4] p62 acts as a link between LC3 and ubiquitinated substrates, which is degraded in autolysosome by autophagy, thus, autophagy activation lowers the p62 levels in the dopaminergic cells. Activating the autophagy and non-canonical Nrf2 pathway is simultaneously possible only under high levels of p62 gene expressions. Interestingly, the protein quantification results confirm that SMER28 treatments increase p62 levels in the dopaminergic cells as high as to be effective in both of the processes, (i.e. autophagy and non-canonical Nrf2 pathways) which renders them to be both simultaneously active in the cells.
Regarding evaluated microgliosis, immunostaining results showed that inflammation is occurred due to 6-OHDAinduced Parkinson rat model development. We showed that microgliosis is common in this models. SMER28 could effectively attenuate microgliosis in the SNc that can be shown by reducing Iba1-immunopositivity in the SMER28-treated group. Microglia are major producers of inflammatory mediators that exacerbate the production of reactive oxygen and nitrogen species in the SN. To combat oxidative stress, microglia, along with other cells of the central nervous system, produce endogenous antioxidants that are regulated predominately through the Nrf2/ARE pathway. In 1988, the potential role for inflammation in PD pathogenesis was suggested when McGeer's group when they demonstrated an increase in reactive microglia in the SN of PD brains [37] . Since that time, many studies showed that glial activation is present in the early stages of PD and this activation increases as the disease progress [38, 39] . Previous studies targeting the nigrostriatal pathway also substantiate a role for microglial activation and oxidative stress in response to PD relevant stressors prior to neuron death [40, 41] . Furthermore, in Nrf2-knockout mice exposed to the nigrostriatal neurotoxicant, MPTP have enhanced microgliosis with increasing the levels of pro-inflammatory markers and decreasing expression of proteins associated with alternative activation. These support the presence of a role for Nrf2 in modulating microglial activation states [42] .
The other interesting target for a novel PD therapy is the antioxidant transcription factor of Nrf2. The activators of Nrf2 such as sulforaphane, BG-12, curcumin, and Protandim are effective in both in vitro and in vivo models of cancer, diabetes, inflammatory disorders and neurodegenerative diseases [43] . One study has shown that SMER28 induces autophagy and alleviates symptoms of Alzheimer's disease through mTOR-independent pathway [44] . A body of evidence shows that SMER28 in combination with other appropriate drugs can be more effective in the treatment of multiple sclerosis [45, 46] . New drugs can be more effective as they target more than one signaling pathways. This can augment cell survival and actually acts through activations of pleiotropic pathways such as antioxidant and autophagy. Treatment with SMER28 Lowers 6-OHDA induced oxidative damage by activating the Nrf2/P62 non-conical pathway.
Conclusion
In conclusion, the current study showed the effectiveness of SMER28 on treatments of the rat model of Parkinsone's disease.
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